The New York drug developer raised $237 million and signed data deals with Bristol Myers Squibb and Tempus to train AI agents on Alzheimer's disease.
Former OpenAI science chief Kevin Weil launched a startup that trains robots to run drug-discovery chemistry in the U.S., backed by $215 million led by Lightspeed.
The day's crypto and finance news, one call and one chart. Weekdays at 7am ET.